Navigation Links
Otonomy Enrolls First Patient in Pivotal Phase 2b Study of OTO-104 in Meniere's Disease
Date:12/11/2013

SAN DIEGO, Dec. 11, 2013 /PRNewswire/ -- Otonomy, Inc., a clinical stage biopharmaceutical company developing innovative therapeutics for diseases and disorders of the inner and middle ear, today announced enrollment of the first patient in its pivotal Phase 2b study of OTO-104 for the reduction of vertigo in patients with unilateral Meniere's disease. The company also announced that the U.S. Food and Drug Administration (FDA) has granted OTO-104 Fast Track designation, a process designed to facilitate the development and expedite the review of drugs to treat serious conditions and fill an unmet medical need.

(Logo: http://photos.prnewswire.com/prnh/20130806/MM59802LOGO)

This prospective, randomized, double-blind, placebo-controlled Phase 2b study is designed to assess the efficacy and safety of OTO-104 for the treatment of Meniere's disease in a total of 140 patients at approximately 50 centers in the United States and Canada. The primary endpoint is the reduction in vertigo frequency at week 12, measured during the 4-week interval from week 9 through week 12, compared to baseline. Otonomy expects to complete patient enrollment of the trial by mid-2014 and announce top line results during the fourth quarter of 2014.

"The commencement of enrollment marks an important clinical milestone for the advancement of OTO-104 as we expect this trial will serve as one of the two studies required to demonstrate efficacy for approval in the United States," said David A. Weber, Ph.D., president and CEO of Otonomy. "The FDA's Fast Track designation shows that the agency recognizes the potential for this product to address the important unmet medical need in Meniere's disease."

Added Paul R. Lambert, M.D., professor and c
'/>"/>

SOURCE Otonomy, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Otonomy Completes $45.9 Million Series C Equity Financing
2. Otonomy Acquires Assets and Patent Rights for Tinnitus Program
3. CalHIPSO Enrolls Over 7,700 Providers in EHR Implementation Program, Hits Other Key Milestones After First Two Years
4. Boehringer Ingelheim Enrolls First Patients in Pivotal Phase 3 Interferon-Free Hepatitis C Trial Program
5. Adynxx Enrolls First Patient in Phase 2 Proof-of-Concept Study for AYX1, Lead Compound for the Prevention of Post-Surgical Pain
6. ROX Medical enrolls first patients in Ireland for CONTROL-HTN hypertension trial at Beaumont and Mater Private Hospitals
7. ROX Medical enrolls first UK patients in CONTROL-HTN hypertension trial at Eastbourne General Hospital
8. Intarcia Enrolls First Patients in "FREEDOM" Global Phase 3 Program for ITCA 650 in Type 2 Diabetes
9. Barts Hospital, London enrolls first patients in ROX Medicals CONTROL-HTN resistant hypertension trial
10. Epizyme Enrolls First Patient in Phase 1/2 Clinical Trial of EPZ-6438, an Inhibitor of EZH2
11. Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/14/2014)...  Mylan Inc. (NASDAQ: MYL ) today announced ... Abbott (NYSE: ABT ) whereby ... markets specialty and branded generics business ("the Assets") in an ... receive 105 million shares of the combined company worth approximately ... Friday, July 11, 2014, representing an approximately 21% ownership stake. ...
(Date:7/11/2014)... , July 11, 2014 Patient ... marketing and, consequently, organizations are turning to an ... As part of this evolving approach ... to educate, communicate and engage patients throughout their ... to patient empowerment. By mapping the patient journey ...
(Date:7/11/2014)... DUBLIN , July 11, 2014 ... "Global Hypodermic Needles Market 2014-2018" report to ... A hypodermic needle is a hollow needle ... the body or or to extract fluids from it. ... liquids or to inject substances that cannot be ingested. ...
Breaking Medicine Technology:Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 2Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 3Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 4Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 5Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 6Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 7Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 8Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 9Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 10Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 11New Study Uses Six-Step Patient Journey as Framework for Consumer-Focused Marketing Opportunities 2Global Hypodermic Needles Market 2014-2018: Key Vendors are Becton, Dickinson and Co, Covidien, Retractable Technologies and Terumo Corp. 2Global Hypodermic Needles Market 2014-2018: Key Vendors are Becton, Dickinson and Co, Covidien, Retractable Technologies and Terumo Corp. 3
... International Myeloma Workshop held in,Kos, Greece ... with bortezomib, dexamethasone and lenalidomide plus,dexamethasone, ... as a single agent in patients ... 29, 2007 /PRNewswire-FirstCall/ -- Keryx,Biopharmaceuticals, Inc. ...
... 2007--A cervical cancer vaccine has shown 90%,efficacy for prevention ... papillomavirus (HPV) types targeted by,the vaccine, conclude authors of ... of The Lancet., HPV types 16 and 18 account ... there are up to 15,oncogenic HPV types which can ...
Cached Medicine Technology:Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase,II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple,Myeloma and Waldenstrom's Macroglobulinemia 2Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase,II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple,Myeloma and Waldenstrom's Macroglobulinemia 3Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase,II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple,Myeloma and Waldenstrom's Macroglobulinemia 4Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase,II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple,Myeloma and Waldenstrom's Macroglobulinemia 5Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase,II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple,Myeloma and Waldenstrom's Macroglobulinemia 6Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase,II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple,Myeloma and Waldenstrom's Macroglobulinemia 7Vaccine Can Prevent Cervical Cancer and Precancerous Lesions 2
(Date:7/14/2014)... 14, 2014 According to the Boost Your Bust ... for women who want to learn how to increase the size ... consists of 7 chapters including:, , Chapter 1 ... Chapter 2 – How Natural Breast Enlargement Works , ... Look Bigger , Chapter 4 – The Groundwork , ...
(Date:7/14/2014)... (PRWEB) July 14, 2014 In ... carriers emphasized lower-cost narrow-network products, accountable care organizations ... chose coverage based on price, rather than on ... from seeking care from out-of-network providers. “Using ... Narrow Networks and Exchange Products,” the July ...
(Date:7/14/2014)... EnergyFirst, manufacturer of all-natural ... Permalean for its great products, thriving customer base, ... markets its products as Jim’s Permalean Protein Powders and ... EnergyFirst’s lineup of nutritional products. The Permalean brand ... year. , Founded in 1999, Permalean’s products were designed ...
(Date:7/14/2014)... CA (PRWEB) July 14, 2014 Crystal ... new office in Sacramento. The announcement has been made via ... office. In addition, the announcement has been made in order ... dental services in the Sacramento area. , Crystal Dental offers ... Some of the services offered by Crystal Dental include cosmetic ...
(Date:7/13/2014)... The special two-day sale starts today on the fan-favorite ... code 20SCRUB at the webstore checkout. The sale expires midnight ... Citrus Scrub falls in love with it," says Sublime ... cleanser for face, but can also be used on the ... exfoliate with pleasure, clean pores and wash away dead skin ...
Breaking Medicine News(10 mins):Health News:Boost Your Bust Book Review Exposes Jenny Bolton's Breast Enhancement Guide – Vkool.com 2Health News:Boost Your Bust Book Review Exposes Jenny Bolton's Breast Enhancement Guide – Vkool.com 3Health News:Milliman, FAIR Health Executives to Discuss Data-Based Rate Setting for Out-of-Network Providers in Atlantic Information Services Webinar 2Health News:EnergyFirst Acquires Permalean - Manufacturer of All Natural Protein Bars and Powders 2Health News:EnergyFirst Acquires Permalean - Manufacturer of All Natural Protein Bars and Powders 3Health News:Crystal Dental Announces the Opening of New Office Location in Sacramento 2Health News:Discover the Favorite Sublime Beauty® Citrus Scrub: Special "Two-Day Only" Sale 2
... , ... Physical Examination of Refrigerated Vacuum Pak or Modified Atmosphere Packaged Raw Fish and Fishery ... ship modified atmosphere or vacuum packed, raw seafood into the US. , ... (Vocus) June 7, 2010 -- ...
... The new Acrylic ... clients can purchase this walk in tub for the same cost of a lesser quality fiberglass ... (PRWEB) May 28, ... in tub available. And now clients can purchase this walk in tub for the same cost ...
... skills in the process, experts say , FRIDAY, June 4 ... spent at the beach or lake, afternoon bike rides and ... likely to be lived in the not-so-great indoors, with kids ... , The indoor child phenomenon concerns health experts and environmentalists, ...
... ... advanced site-search and personalization, with easier management tools, obtaining better ROI , ... Rochester, NY and Piscataway NJ ... e-commerce applications and Celebros, a global leader in revenue optimizing solutions for online stores, ...
... Institute (NHLBI) has stopped a clinical trial evaluating a new ... with sickle cell anemia and iron overload because of evidence ... the existing treatment. The 26-site trial, Stroke With ... the ages of 5 and 18 who had already experienced ...
... complications, death in elderly who don,t delay surgery, research ... elderly patients, prompt removal of a suddenly inflamed gallbladder ... shows. , In the study, Dr. Taylor S. Riall, ... Medical Branch in Galveston, and colleagues analyzed data on ...
Cached Medicine News:Health News:FDA Issues Global Raw Packaged Seafood Import Alert: FDAImports.com Reports Numerous International Firms Impacted 2Health News:FDA Issues Global Raw Packaged Seafood Import Alert: FDAImports.com Reports Numerous International Firms Impacted 3Health News:The Walkinbathtub1 Factory After Years in Design Has Released the Most Up to date Acrylic Walk in Tub in the World 2Health News:The Walkinbathtub1 Factory After Years in Design Has Released the Most Up to date Acrylic Walk in Tub in the World 3Health News:Move Childhood Back Outdoors This Summer 2Health News:Move Childhood Back Outdoors This Summer 3Health News:UniteU and Celebros Launch Dynamic Cross-Sell and New Version of Filtered Navigation Search 2Health News:UniteU and Celebros Launch Dynamic Cross-Sell and New Version of Filtered Navigation Search 3Health News:Stroke prevention study in children with sickle cell anemia, iron overload stopped early 2Health News:Stroke prevention study in children with sickle cell anemia, iron overload stopped early 3Health News:Removing Gallbladder Sooner Cuts Costs, Readmissions 2
OKN drum...
Accurately tests for Nystagmus when rotated at 8-10 rpm. Drums are 10" high by 8" diameter. Light weight drum of professional quality with ball bearings for effortless spin mechanism. For use 24 to 3...
Diagnose dry eye, assess the effectiveness of permanent punctal occlusion, collagen - dissolvable in 3-5 days, all are 2 mm long. Sterile...
The rectangular large-field lens of the 2631 are ideal for reading and writing....
Medicine Products: